Our medicines
We believe in the power of science to tackle some of the most challenging diseases of our time. We have a long history of developing life-saving medicines and a promising pipeline to shape the next generation of treatment options across multiple indications and in 4 therapeutic areas.
For information and questions about risk management regarding Bristol Myers Squibb products and the Pregnancy Prevention Program, please contact Bristol Myers Squibb's Patient Safety Department at:
E-mail: safety_netherlands@bms.com
Phone: +31 (0)30 300 2222
This visual gives an overview of the reimbursed medicines of Bristol Myers Squibb in the Netherlands in October 2024.
This is an overview of all Bristol Myers Squibb medicines, both reimbursed and non-reimbursed.
ABECMA (idecabtagene vicleucel)
ABRAXANE (paclitaxel)
BARACLUDE (entecavir)
BREYANZI (lisocabtagene maraleucel)
CAMZYOS (mavacamten)
ELIQUIS (apixaban)
EMPLICITI (elotuzumab)
IMNOVID (pomalidomide)
KENACORT A-10 (triamcinolonacetonide)
KENACORT A-40 (triamcinolonacetonide)
KRAZATI (adagrasib)
NULOJIX (belatacept)
ONUREG (azacitidine)
OPDIVO (nivolumab)
OPDUALAG (nivolumab and relatlimab)
ORENCIA 250 mg powder for concentrate for solution for infusion (abatacept)
ORENCIA 125 mg solution for injection in a pre-filled syringe (abatacept)
ORENCIA 125 mg solution for injection in pre-filled pen (abatacept)
REBLOZYL (luspatercept)
REVLIMID (lenalidomide)
SOTYKTU (deucravacitinib)
SPRYCEL (dasatinib)
VIDAZA (azacitidine)
YERVOY (ipilimumab)
ZEPOSIA (ozanimod)